维立西呱治疗慢性心力衰竭的效果分析

Analysis on Effect of Vericiguat in Treatment of Chronic Heart Failure

目的:分析维立西呱治疗慢性心力衰竭的效果。方法:选取2023年6月—2024年1月昌乐县人民医院收治的慢性心力衰竭患者110例作为研究对象,采用随机数字表法分为对照组与研究组,各55例。对照组实施常规抗心力衰竭治疗,研究组在对照组基础上给予维立西呱治疗。比较两组治疗效果。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P=0.028)。治疗后,两组N末端B型利钠肽前体水平低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组左室射血分数高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组胸闷气短、呼吸困难、腿部水肿评分低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前后,两组天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、尿素氮、血肌酐水平比较,差异无统计学意义(P>0.05)。结论:维立西呱治疗慢性心力衰竭的效果显著,能够有效改善心功能,减轻临床症状,且安全性较好。

Objective:To analyze the effect of vericiguat in the treatment of chronic heart failure.Methods:A total of 110 patients with chronic heart failure admitted to Changle People's Hospital from June 2023 to January 2024 were selected as the study subjects.They were divided into control group and study group according to random number table method,with 55 cases in each group.The control group was given routine anti-heart failure therapy,and the study group was treated with vericiguat on the basis of the control group.The treatment effects were compared between the two groups.Results:The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P=0.028).After treatment,the level of N-terminal pro-B-type natriuretic peptide in the two groups was lower than that before treatment,and the level in the study group was lower than that in the control group,with a statistically significant difference(P<0.05);The left ventricular ejection fraction in the two groups was higher than that before treatment,and this index in the study group was higher than that in the control group,with a statistically significant difference(P<0.05).After treatment,the scores of chest tightness,shortness of breath,dyspnea and leg edema in the two groups were lower than those before treatment,and the scores in the study group were lower than those in the control group,with a statistically significant difference(P<0.05).Before and after treatment,there was no significant difference in the levels of aspartate aminotransferase,alanine aminotransferase,urea nitrogen and serum creatinine between the two groups(P>0.05).Conclusion:Vericiguat has a significant effect in the treatment of chronic heart failure,and can effectively improve cardiac function,relieve clinical symptoms,and has a good safety profile.